Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
Phase II Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving AR Blockade and AR Blockade + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to AR blockade that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Clinical Trial Recruitment Navigator
- 电话号码:310-423-5842
- 邮箱:GroupCancerTrialInformation@cshs.org
研究联系人备份
- 姓名:Edwin Posadas, MD FACP
- 邮箱:edwin.posadas@csmc.edu
学习地点
-
-
California
-
Duarte、California、美国、91010
- 招聘中
- City of Hope
-
接触:
- Tanya Dorff, MD
- 电话号码:626-256-4673
- 邮箱:tdorff@coh.org
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars-Sinai Medical Center
-
副研究员:
- David Hoffman, MD
-
副研究员:
- Robert Figlin, MD FACP
-
副研究员:
- Kevin Scher, MD MBA
-
副研究员:
- Leland Green, MD
-
副研究员:
- Kristopher Wentzel, MD
-
副研究员:
- Jun Gong, MD
-
接触:
- Clinical Trial Recruitment Navigator
- 电话号码:310-423-5842
- 邮箱:GroupCancerTrialInformation@cshs.org
-
接触:
- Edwin Posadas
- 邮箱:edwin.posadas@csmc.edu
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 招聘中
- Huntsman Cancer Institute and Hospital
-
接触:
- Umang Swami, MD
- 电话号码:801-587-4381
- 邮箱:Umang.Swami@hci.utah.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
History of castration-resistant prostate cancer with rising PSA on a contemporary ARSI (e.g. abiraterone or, enzalutamide, darolutamide). Bicalutamide, nilutamide, and flutamide will not be considered as contemporary ARSIs.
- PSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least 2 separate occasions greater than 1 week apart while on an ARSI
- Patient must be surgically castrated or have serum testosterone concentrations much be consistent with castrate levels of testosterone (under 50 ng/dL) while on LHRH analog therapy
- Patient must have had 1 and can have up to 2 prior AR targeted agents (if patients have had previous enzalutamide, they will be considered only for arm C). therapy with the exception of apalutamide.
- Patients may not have had previous chemotherapy with the exception of docetaxel administered for castration-sensitive disease.
-
Patients must decline or be ineligible for taxane therapy in the opinion of the treating physician.
-
Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
-
Resolution of adverse events results as described below:
- If the subject's patient's most recent line of therapy is treatment with abiraterone or enzalutamide, then all adverse events must be resolved to Grade 2 or less
- If the subject's patient's most recent line of therapy is any other treatment for mCRPC then all Adverse events must be resolved to grade 1 or less, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2)
-
Adequate organ function
-
All patients must agree to use an adequate method of contraception, in the opinion of the treating investigator, while on protocol treatment and for 3 months after the last dose of protocol treatment (apalutamide/enzalutamide and/or carotuximab)
-
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
Exclusion Criteria:
- Non-PSA producing prostate cancers such as small cell prostate cancers or those prostate cancers which exhibit radiographic progression without PSA rise
- Other prior malignancy requiring active anticancer therapy
- Prior exposure to carotuximab or any CD105 targeted antibody
- Any major surgical procedure, in the opinion of the treating physician, within 2 weeks of starting therapy
- Uncontrolled chronic hypertension defined as sustained systolic pressure (SBP) >150 mmHg or diastolic pressure (DBP) >90 despite optimal therapy
- Active bleeding or pathologic medical conditions, including but not limited to factor deficiencies, hemophilia, etc., that carries a high bleeding risk
- Use of thrombolytics within 10 days prior to the first day of carotuximab
- Known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies
- A known diagnosis of Osler-Weber-Rendu syndrome
- Ascites or pericardial or pleural effusion requiring external drainage procedures
- History of untreated brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days. Imaging for CNS disease will not be required for screening unless there is a history of a neurological finding such as new onset of weakness or numbness that cannot be explained by other medical history.
- Acute cardiovascular event within the past 6 months. An acute cardiovascular event will be defined as a myocardial infarction, NYHA Class II or worse congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG.
- Deep venous thrombosis within the past 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred but clearance should be given by the local PI.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Enzalutamide Naive - Monotherapy
After progression, subjects will crossover to combination therapy |
Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle
其他名称:
|
|
实验性的:Enzalutamide Naive - Combination therapy (Androgen Receptor Blockade + Carotuximab)
Androgen Receptor is Apalutamide 240mg for Lead-In group & Enzalutamide 160mg for all other groups |
Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle
其他名称:
Carotuximab administered intravenously at the following doses: Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose. |
|
实验性的:Enzalutamide Exposed - Combination therapy (Androgen Receptor Blockade + Carotuximab)
Androgen Receptor is Apalutamide 240mg for Lead-In group & Enzalutamide 160mg for all other groups |
Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle
其他名称:
Carotuximab administered intravenously at the following doses: Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression free survival (rPFS) between patients receiving AR blockade and AR blockade + carotuximab
大体时间:From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause. |
From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Adverse events (grade 3 or higher) related to carotuximab and AR blockade
大体时间:From start of study treatment through 4 weeks on treatment
|
Grade 3 or above treatment related adverse events as assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
From start of study treatment through 4 weeks on treatment
|
|
Overall radiographic response rate (ORR) of the combination of AR blockade + carotuximab
大体时间:From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
Participants of the combination of AR blockade + carotuximab, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3 |
From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
|
Proportion of patients resistant to AR blockade benefit from the addition of carotuximab
大体时间:From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
Participants of the monotherapy group that crossover to combination therapy at progression, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3 |
From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
|
Overall radiographic response rate (ORR) in the overall population
大体时间:From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
Determined by confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3 |
From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
|
To determine the radiographic progression free survival (rPFS) in the overall population
大体时间:From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause. |
From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
|
To determine the biochemical PFS (by PCWG3) in the overall population
大体时间:From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
From the start of study treatment until documented progression, per Prostate Cancer Working Group 3, or death due to any cause. |
From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
合作者和调查者
合作者
调查人员
- 首席研究员:Edwin Posadas, MD FACP、Cedars-Sinai Medical Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.